These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 10069876

  • 1. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
    FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, Brambilla R.
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
    [Abstract] [Full Text] [Related]

  • 2. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
    Rosenthal RR, Busse WW, Kemp JP, Baker JW, Kalberg C, Emmett A, Rickard KA.
    Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
    [Abstract] [Full Text] [Related]

  • 3. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.
    Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P, French FOR-F-01 Study Group.
    Respir Med; 2001 Jan; 95(1):64-70. PubMed ID: 11207020
    [Abstract] [Full Text] [Related]

  • 4. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ, Winter TH, Aalbers R.
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of treatment with formoterol on bronchoprotection against methacholine.
    Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D.
    Am J Med; 1998 May; 104(5):431-8. PubMed ID: 9626025
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 14. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
    Kalra S, Swystun VA, Bhagat R, Cockcroft DW.
    Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
    [Abstract] [Full Text] [Related]

  • 15. Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma.
    Yates DH, Peters MJ, Keatings V, Thomas PS, Barnes PJ.
    Eur Respir J; 1995 Nov; 8(11):1847-51. PubMed ID: 8620950
    [Abstract] [Full Text] [Related]

  • 16. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
    van Schayck CP, Cloosterman SG, Bijl-Hofland ID, van den Hoogen H, Folgering HT, van Weel C.
    Respir Med; 2002 Mar; 96(3):155-62. PubMed ID: 11908511
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.